Cargando…

Evaluation of two family-based intervention programs for children affected by rare disease and their families – research network (CARE-FAM-NET): study protocol for a rater-blinded, randomized, controlled, multicenter trial in a 2x2 factorial design

BACKGROUND: Families of children with rare diseases (i.e., not more than 5 out of 10,000 people are affected) are often highly burdened with fears, insecurities and concerns regarding the affected child and its siblings. Although families caring for children with rare diseases are known to be at ris...

Descripción completa

Detalles Bibliográficos
Autores principales: Boettcher, Johannes, Filter, Bonnie, Denecke, Jonas, Hot, Amra, Daubmann, Anne, Zapf, Antonia, Wegscheider, Karl, Zeidler, Jan, von der Schulenburg, J.-Matthias Graf, Bullinger, Monika, Rassenhofer, Miriam, Schulte-Markwort, Michael, Wiegand-Grefe, Silke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678588/
https://www.ncbi.nlm.nih.gov/pubmed/33218310
http://dx.doi.org/10.1186/s12875-020-01312-9
_version_ 1783612188398714880
author Boettcher, Johannes
Filter, Bonnie
Denecke, Jonas
Hot, Amra
Daubmann, Anne
Zapf, Antonia
Wegscheider, Karl
Zeidler, Jan
von der Schulenburg, J.-Matthias Graf
Bullinger, Monika
Rassenhofer, Miriam
Schulte-Markwort, Michael
Wiegand-Grefe, Silke
author_facet Boettcher, Johannes
Filter, Bonnie
Denecke, Jonas
Hot, Amra
Daubmann, Anne
Zapf, Antonia
Wegscheider, Karl
Zeidler, Jan
von der Schulenburg, J.-Matthias Graf
Bullinger, Monika
Rassenhofer, Miriam
Schulte-Markwort, Michael
Wiegand-Grefe, Silke
author_sort Boettcher, Johannes
collection PubMed
description BACKGROUND: Families of children with rare diseases (i.e., not more than 5 out of 10,000 people are affected) are often highly burdened with fears, insecurities and concerns regarding the affected child and its siblings. Although families caring for children with rare diseases are known to be at risk for mental disorders, the evaluation of special programs under high methodological standards has not been conducted so far. Moreover, the implementation of interventions for this group into regular care has not yet been accomplished in Germany. The efficacy and cost-effectiveness of a family-based intervention will be assessed. METHODS/DESIGN: The study is a 2x2 factorial randomized controlled multicenter trial conducted at 17 study centers throughout Germany. Participants are families with children and adolescents affected by a rare disease aged 0 to 21 years. Families in the face-to-face intervention CARE-FAM, online intervention WEP-CARE or the combination of both will be treated over a period of roughly 6 months. Topics discussed in the interventions include coping, family relations, and social support. Families in the control condition will receive treatment as usual. The primary efficacy outcome is parental mental health, measured by the Structured Clinical Interview for DSM-IV (SCID-I) by blinded external raters. Further outcomes will be assessed from the parents’ as well as the children’s perspective. Participants are investigated at baseline, 6, 12 and 18 months after randomization. In addition to the assessment of various psychosocial outcomes, a comprehensive health-economic evaluation will be performed. DISCUSSION: This paper describes the implementation and evaluation of two family-based intervention programs for Children Affected by Rare Disease and their Family’s Network (CARE-FAM-NET) in German standard care. A methodologically challenging study design is used to reflect the complexity of the actual medical care situation. This trial could be an important contribution to the improvement of care for this highly burdened group. TRIAL REGISTRATION: German Clinical Trials Register: DRKS00015859 (registered 18 December 2018) and ClinicalTrials.gov: NCT04339465 (registered 8 April 2020). Protocol Version: 15 August 2020 (Version 6.1). Trial status: Recruitment started on 1 January 2019 and will be completed on 31 March 2021. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12875-020-01312-9.
format Online
Article
Text
id pubmed-7678588
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-76785882020-11-23 Evaluation of two family-based intervention programs for children affected by rare disease and their families – research network (CARE-FAM-NET): study protocol for a rater-blinded, randomized, controlled, multicenter trial in a 2x2 factorial design Boettcher, Johannes Filter, Bonnie Denecke, Jonas Hot, Amra Daubmann, Anne Zapf, Antonia Wegscheider, Karl Zeidler, Jan von der Schulenburg, J.-Matthias Graf Bullinger, Monika Rassenhofer, Miriam Schulte-Markwort, Michael Wiegand-Grefe, Silke BMC Fam Pract Study Protocol BACKGROUND: Families of children with rare diseases (i.e., not more than 5 out of 10,000 people are affected) are often highly burdened with fears, insecurities and concerns regarding the affected child and its siblings. Although families caring for children with rare diseases are known to be at risk for mental disorders, the evaluation of special programs under high methodological standards has not been conducted so far. Moreover, the implementation of interventions for this group into regular care has not yet been accomplished in Germany. The efficacy and cost-effectiveness of a family-based intervention will be assessed. METHODS/DESIGN: The study is a 2x2 factorial randomized controlled multicenter trial conducted at 17 study centers throughout Germany. Participants are families with children and adolescents affected by a rare disease aged 0 to 21 years. Families in the face-to-face intervention CARE-FAM, online intervention WEP-CARE or the combination of both will be treated over a period of roughly 6 months. Topics discussed in the interventions include coping, family relations, and social support. Families in the control condition will receive treatment as usual. The primary efficacy outcome is parental mental health, measured by the Structured Clinical Interview for DSM-IV (SCID-I) by blinded external raters. Further outcomes will be assessed from the parents’ as well as the children’s perspective. Participants are investigated at baseline, 6, 12 and 18 months after randomization. In addition to the assessment of various psychosocial outcomes, a comprehensive health-economic evaluation will be performed. DISCUSSION: This paper describes the implementation and evaluation of two family-based intervention programs for Children Affected by Rare Disease and their Family’s Network (CARE-FAM-NET) in German standard care. A methodologically challenging study design is used to reflect the complexity of the actual medical care situation. This trial could be an important contribution to the improvement of care for this highly burdened group. TRIAL REGISTRATION: German Clinical Trials Register: DRKS00015859 (registered 18 December 2018) and ClinicalTrials.gov: NCT04339465 (registered 8 April 2020). Protocol Version: 15 August 2020 (Version 6.1). Trial status: Recruitment started on 1 January 2019 and will be completed on 31 March 2021. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12875-020-01312-9. BioMed Central 2020-11-20 /pmc/articles/PMC7678588/ /pubmed/33218310 http://dx.doi.org/10.1186/s12875-020-01312-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Study Protocol
Boettcher, Johannes
Filter, Bonnie
Denecke, Jonas
Hot, Amra
Daubmann, Anne
Zapf, Antonia
Wegscheider, Karl
Zeidler, Jan
von der Schulenburg, J.-Matthias Graf
Bullinger, Monika
Rassenhofer, Miriam
Schulte-Markwort, Michael
Wiegand-Grefe, Silke
Evaluation of two family-based intervention programs for children affected by rare disease and their families – research network (CARE-FAM-NET): study protocol for a rater-blinded, randomized, controlled, multicenter trial in a 2x2 factorial design
title Evaluation of two family-based intervention programs for children affected by rare disease and their families – research network (CARE-FAM-NET): study protocol for a rater-blinded, randomized, controlled, multicenter trial in a 2x2 factorial design
title_full Evaluation of two family-based intervention programs for children affected by rare disease and their families – research network (CARE-FAM-NET): study protocol for a rater-blinded, randomized, controlled, multicenter trial in a 2x2 factorial design
title_fullStr Evaluation of two family-based intervention programs for children affected by rare disease and their families – research network (CARE-FAM-NET): study protocol for a rater-blinded, randomized, controlled, multicenter trial in a 2x2 factorial design
title_full_unstemmed Evaluation of two family-based intervention programs for children affected by rare disease and their families – research network (CARE-FAM-NET): study protocol for a rater-blinded, randomized, controlled, multicenter trial in a 2x2 factorial design
title_short Evaluation of two family-based intervention programs for children affected by rare disease and their families – research network (CARE-FAM-NET): study protocol for a rater-blinded, randomized, controlled, multicenter trial in a 2x2 factorial design
title_sort evaluation of two family-based intervention programs for children affected by rare disease and their families – research network (care-fam-net): study protocol for a rater-blinded, randomized, controlled, multicenter trial in a 2x2 factorial design
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678588/
https://www.ncbi.nlm.nih.gov/pubmed/33218310
http://dx.doi.org/10.1186/s12875-020-01312-9
work_keys_str_mv AT boettcherjohannes evaluationoftwofamilybasedinterventionprogramsforchildrenaffectedbyrarediseaseandtheirfamiliesresearchnetworkcarefamnetstudyprotocolforaraterblindedrandomizedcontrolledmulticentertrialina2x2factorialdesign
AT filterbonnie evaluationoftwofamilybasedinterventionprogramsforchildrenaffectedbyrarediseaseandtheirfamiliesresearchnetworkcarefamnetstudyprotocolforaraterblindedrandomizedcontrolledmulticentertrialina2x2factorialdesign
AT deneckejonas evaluationoftwofamilybasedinterventionprogramsforchildrenaffectedbyrarediseaseandtheirfamiliesresearchnetworkcarefamnetstudyprotocolforaraterblindedrandomizedcontrolledmulticentertrialina2x2factorialdesign
AT hotamra evaluationoftwofamilybasedinterventionprogramsforchildrenaffectedbyrarediseaseandtheirfamiliesresearchnetworkcarefamnetstudyprotocolforaraterblindedrandomizedcontrolledmulticentertrialina2x2factorialdesign
AT daubmannanne evaluationoftwofamilybasedinterventionprogramsforchildrenaffectedbyrarediseaseandtheirfamiliesresearchnetworkcarefamnetstudyprotocolforaraterblindedrandomizedcontrolledmulticentertrialina2x2factorialdesign
AT zapfantonia evaluationoftwofamilybasedinterventionprogramsforchildrenaffectedbyrarediseaseandtheirfamiliesresearchnetworkcarefamnetstudyprotocolforaraterblindedrandomizedcontrolledmulticentertrialina2x2factorialdesign
AT wegscheiderkarl evaluationoftwofamilybasedinterventionprogramsforchildrenaffectedbyrarediseaseandtheirfamiliesresearchnetworkcarefamnetstudyprotocolforaraterblindedrandomizedcontrolledmulticentertrialina2x2factorialdesign
AT zeidlerjan evaluationoftwofamilybasedinterventionprogramsforchildrenaffectedbyrarediseaseandtheirfamiliesresearchnetworkcarefamnetstudyprotocolforaraterblindedrandomizedcontrolledmulticentertrialina2x2factorialdesign
AT vonderschulenburgjmatthiasgraf evaluationoftwofamilybasedinterventionprogramsforchildrenaffectedbyrarediseaseandtheirfamiliesresearchnetworkcarefamnetstudyprotocolforaraterblindedrandomizedcontrolledmulticentertrialina2x2factorialdesign
AT bullingermonika evaluationoftwofamilybasedinterventionprogramsforchildrenaffectedbyrarediseaseandtheirfamiliesresearchnetworkcarefamnetstudyprotocolforaraterblindedrandomizedcontrolledmulticentertrialina2x2factorialdesign
AT rassenhofermiriam evaluationoftwofamilybasedinterventionprogramsforchildrenaffectedbyrarediseaseandtheirfamiliesresearchnetworkcarefamnetstudyprotocolforaraterblindedrandomizedcontrolledmulticentertrialina2x2factorialdesign
AT schultemarkwortmichael evaluationoftwofamilybasedinterventionprogramsforchildrenaffectedbyrarediseaseandtheirfamiliesresearchnetworkcarefamnetstudyprotocolforaraterblindedrandomizedcontrolledmulticentertrialina2x2factorialdesign
AT wiegandgrefesilke evaluationoftwofamilybasedinterventionprogramsforchildrenaffectedbyrarediseaseandtheirfamiliesresearchnetworkcarefamnetstudyprotocolforaraterblindedrandomizedcontrolledmulticentertrialina2x2factorialdesign